DRRX DURECT Corporation

+0.02  (2%)
Previous Close 1.26
Open 1.25
Price To book 54.78
Market Cap 181.72M
Shares 141,966,000
Volume 1,157,611
Short Ratio 6.89
Av. Daily Volume 848,238

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 17831116
  2. 8-K - Current report 17831022
  3. 8-K - Current report 17820569
  4. DEF 14A - Other definitive proxy statements 17789784
  5. 8-K - Current report 17777707

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial likely to be initiated in 2017.
Primary sclerosing cholangitis (PSC)
CRL issued February 12, 2014.
Post-operative pain relief
CRL Feb 12 2014. Phase 3 commenced November 2015 in response to CRL. Enrolment originally expected to take one year but the company announced ammendments to the trial on April 7, 2016, which will result in time added to complete the trial. Dosing to be completed 2Q 2017 with with top-line data 4Q 2017.
Post-operative pain relief
Phase 3 to be initiated by ZGNX once partner is found.
Phase 1b dosing progressed to higher dosage - announced October 31, 2016. Data presented at EASL April 24, 2017.
Nonalcoholic steatohepatitis (NASH)
CRL issued September 26, 2016. Noted March 20, 2017 that it intends to resubmit the NDA following additional trials to be completed by the end of 2017.
Chronic pain

Latest News

  1. ETFs with exposure to DURECT Corp. : May 26, 2017
  2. The Life Sciences Report Interviews H.C. Wainwright Analyst Ed Arce
  3. Edited Transcript of DRRX earnings conference call or presentation 10-May-17 8:30pm GMT
  4. Synergy Pharmaceuticals and Durect Corporation Both Sail Higher on Trader Optimism
  5. DURECT Corp. :DRRX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
  6. The Life Sciences Report Examines DURECT and Sandoz's $293 Million Deal for POSIMIR
  7. Durect reports 1Q loss
  8. DURECT Corporation Announces First Quarter 2017 Financial Results and Provides Corporate Update
  9. Today’s Research Reports on Stocks to Watch: Amyris and DURECT
  10. DURECT(DRRX): A $293 Million Deal with Sandoz for POSIMIR® in the United States
  11. DURECT and Sandoz have Signed a $293 Million Development and Commercialization Agreement for POSIMIR® (SABER®-Bupivacaine) Covering the United States
  12. DURECT Corporation Invites You to Join its First Quarter 2017 Earnings Conference Call
  13. ETFs with exposure to DURECT Corp. : April 27, 2017
  14. The Life Sciences Report Examines How Trial Results Set Up DURECT Corp. for 'Exciting Year'
  15. NASH: The next untapped pharma market gives investors many options
  16. DURECT Announces Presentation of Data from a Phase 1b Study of DUR-928 in Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress™ 2017
  17. DURECT to Present Clinical Data at the International Liver Congress™ 2017
  18. DURECT to Present at the H.C. Wainwright NASH Investor Conference
  19. The Life Sciences Report Interviews DURECT Corp. President and CEO James Brown